DRG Epidemiology's coverage of hyperkalemia comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of hyperkalemia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan in this report.

DRG Epidemiology's hyperkalemia forecast will answer the following questions:

  • Of all people with hyperkalemia, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with hyperkalemia, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of hyperkalemia over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following hyperkalemia patient populations:

  • Total Prevalent Cases of Hyperkalemia
  • Total Prevalent Cases by Severity
  • Diagnosed subpopulation(s)
  • Treatment subpopulation(s)
  • Hyperkalemia Related Hospitalization Events
  • Hyperkalemia Related Hospitalization Events by Acute Status

Note: coverage may vary by country and region.

Table of contents

  • Mature Markets Data
    • Introduction
      • Key Findings
      • Overview
        • Prevalence of Hyperkalemia per 1,000 Among People Aged 20+ in 2016 and 2026
        • Relative Sizes of Contributing Factors to the Trend in Total Prevalent Cases of Hyperkalemia Over the Next Ten Years
        • Analysis of Total Prevalent Cases by Diagnosed and Drug-Treated Status
        • Analysis of the Total Prevalent Cases of Hyperkalemia in 2016 by Severity
        • Event Rate of Hyperkalemia per 1,000 Among People Aged 20+ in 2016 and 2026
    • Epidemiology Data
    • Methods
      • Total Prevalent Cases of Hyperkalemia
      • Severity of Hyperkalemia
      • Diagnosed Prevalent Cases of Hyperkalemia
      • Drug-Treated Prevalent Cases of Hyperkalemia
      • Hospitalization-Related Events of Hyperkalemia
      • Diagnosed Acute Events of Hyperkalemia
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Joseph Granato, MPH

Joseph Granato is a Principal Analyst with the Market Access Insights ; Currently he oversees all datasets related to DRG’s Global Market Access Solutions (GMAS) ; Joseph is responsible for GMAS related data discovery, procurement and ; Through close collaboration with DRG’s technology development team he ensures accurate and timely updates of ; By doing so he helps provide clients the most recent information needed to make informed Market Access decisions across the globe. Joseph Granato has been an analyst with Decision Resources Group since ; He Started as a Research Analyst working with the Data Operations group procuring healthcare enrollment data in the United ; Later, as a Senior Research Analyst he led a small team of analyst while managing DRG’s PatientFinder ; Most recently Joseph transitioned to his current position as a Principal Analyst with the Market Access Insights ; Joseph has a Master’s in Public Health from Des Moines University.